Gland Pharma gets USFDA nod for glaucoma drug
Gland Pharma gets USFDA nod for glaucoma drug. The approval boosts its product portfolio and export potential. Shares rose on NSE following the news. The drug’s launch could contribute revenue of ₹100–150 crore annually in the medium term.
📊 STOCKS: GLAND | 🏢 SECTOR: Pharma | #MEDIUMIMPACT #FDAApproval
This brief is AI-generated from public news sources for informational purposes only. Not investment advice. Always consult a SEBI-registered advisor before trading.